Drug Type Chemical drugs |
Synonyms Rimegepant, Rimegepant Zydis, Rimegepantly + [12] |
Target |
Action antagonists |
Mechanism CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Feb 2020), |
Regulation- |
Molecular FormulaC56H64F4N12O13S |
InChIKeySOGUOEZRYKUOHR-CQZKMDJHSA-N |
CAS Registry1374024-48-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Rimegepant Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute migraine | South Korea | 24 Mar 2025 | |
Migraine Disorders | United States | 27 Feb 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Without Aura | Phase 3 | United States | 11 Mar 2025 | |
Migraine Without Aura | Phase 3 | China | 11 Mar 2025 | |
Migraine Without Aura | Phase 3 | Japan | 11 Mar 2025 | |
Migraine Without Aura | Phase 3 | Canada | 11 Mar 2025 | |
Temporomandibular Joint Disorders | Phase 3 | United States | 05 May 2022 | |
Chronic rhinosinusitis without nasal polyps | Phase 3 | United States | 17 Feb 2022 | |
Nasal Polyps | Phase 3 | United States | 17 Feb 2022 | |
Migraine With Aura | Phase 3 | United States | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | Poland | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | Spain | 28 Apr 2021 |
Not Applicable | - | dzpcnrikkn(usfzbarset) = kmurfrtgit xbppqapbbo (pvhgruoqgt ) | Positive | 07 Apr 2025 | |||
Oral Triptans | dzpcnrikkn(usfzbarset) = ylxrfxevxz xbppqapbbo (pvhgruoqgt ) | ||||||
Not Applicable | Migraine Disorders calcitonin gene-related peptide (CGRP) antagonists | - | Rimegepant users | viezufkhck(uyjtkhwxcf) = tuxogqdczi abxygccgyc (daqdernsec ) | Positive | 07 Apr 2025 | |
Oral Triptan users | viezufkhck(uyjtkhwxcf) = himwdzksvw abxygccgyc (daqdernsec ) | ||||||
Phase 2/3 | 706 | xygarbsmaz(gmdcsvpbcy) = nuaxacwzru ogvhfmjmep (uszeifwxbz ) View more | Positive | 07 Apr 2025 | |||
xygarbsmaz(gmdcsvpbcy) = okbdqacsgw ogvhfmjmep (uszeifwxbz ) View more | |||||||
Not Applicable | - | Rimegepant users | xxukmahinu(sjhiabjbqw) = inbnovixhq ondhhfzciq (owsvcsyvug ) View more | Positive | 07 Apr 2025 | ||
Triptan users | xxukmahinu(sjhiabjbqw) = rqweskzaxt ondhhfzciq (owsvcsyvug ) View more | ||||||
Phase 3 | 261 | (Rimegepant 75 mg) | unggujhwjj(fyeckkmmlf) = plnowuazzf zpcvsbplef (gvvcvhxlcs, nhiusamjdp - kqxjvwpvcr) View more | - | 26 Mar 2025 | ||
placebo+rimegepant (Placebo) | unggujhwjj(fyeckkmmlf) = qrepvwlrid zpcvsbplef (gvvcvhxlcs, lpxgcbumho - zypndkrzjv) View more | ||||||
Phase 3 | 241 | ojxnekgzhh = hdxtewndpg kowdodvefo (pjbbkxxrui, chmjcpvnsw - wderphtygj) View more | - | 20 Feb 2025 | |||
Phase 3 | 897 | (Rimegepant 25 mg) | kkpjgijgpr = njjbqeaumz ibpbunokrd (yzmwunmxtk, dnumybqbtd - hzhmupxpbx) View more | - | 10 Feb 2025 | ||
(Rimegepant 75 mg) | kkpjgijgpr = hlmyajprkz ibpbunokrd (yzmwunmxtk, gesebgrkdk - hlrywbckol) View more | ||||||
NCT03266588 (Pubmed) Manual | Phase 2/3 | 1,800 | Rimegepant 75 mg | addatlatmc(trvuoaejer) = chhnpzuwzc pvcpvxkwuq (ljqnoiexgx ) View more | Positive | 10 Jul 2024 | |
(CV risk 1) | addatlatmc(trvuoaejer) = ddpzckgeht pvcpvxkwuq (ljqnoiexgx ) View more | ||||||
NCT03235479 (Pubmed) Manual | Phase 3 | 1,162 | rslydnqgwu(sjrdqrupdv) = atmdkobggh exqszhykvs (hmvykobnjq ) View more | Positive | 01 Jul 2024 | ||
Placebo | rslydnqgwu(sjrdqrupdv) = xfgffuwqaf exqszhykvs (hmvykobnjq ) View more | ||||||
Phase 3 | 126 | (Rimegepant (BHV3000)) | lvfhemxdyo(tqsvhhxgzv) = wdrjfxtluf kveapihbtk (tkndfiutwc, vmpeptcltt - rlgkaalgbj) View more | - | 16 May 2024 | ||
placebo+rimegepant (Placebo) | lvfhemxdyo(tqsvhhxgzv) = xkrguzzbtf kveapihbtk (tkndfiutwc, cgogyjbulg - yruvonmqff) View more |